From: Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage
Genotypea | LCTRS (n = 61) N (%) | CRC (n = 52) N (%) | p value | OR | Grade I–II (n = 31) N (%) | P value | Grade III–IV (n = 19) N (%) | p value | OR |
---|---|---|---|---|---|---|---|---|---|
AA158 | |||||||||
 CD16A-559T/T | 5 (8.2) | 4 (7.7) | NS | NS | 2 (6.5) | NS | 2 (10.5) | NS | NS |
 CD16A -559G/T | 40 (65.6) | 32 (61.5) | NS | NS | 20 (64.5) | NS | 11 (57.9) | NS | NS |
 CD16A -559G/G | 16 (26.2) | 16 (30.8) | NS | NS | 9 (29.0) | NS | 6 (31.6) | NS | NS |
 CD16A -559GT + TT | 47 (74.6) | 36 (69.2) | NS | NS | 22 (71.0) | NS | 13 (68.4) | NS | NS |
Allele | |||||||||
 CD16A -V158 (G) | 72 (59.0) | 64 (61.5) | NS | NS | 38 (61.3) | NS | 23 (60.5) | NS | NS |
 CD16A -F158 (T) | 50 (41.0) | 40 (38.5) | NS | NS | 24 (38.7) | NS | 15 (39.5) | NS | NS |
AA48 | Â | ||||||||
 CD16A -230A/G | 0 | 1 (1.9) | NS | NS | 0 | NS | 1 (5.3) | NS | NS |
 CD16A -230G/T | 10 (16.4) | 5 (9.6) | NS | NS | 2 (6.5) | NS | 3 (15.8) | NS | NS |
 CD16A -230G/G | 2 (3.3) | 0 | NS | NS | 0 | NS | 0 | NS | NS |
 CD16A -230T/T | 43 (70.5) | 34 (65.4) | NS | NS | 21 (67.7) | NS | 11 (57.9) | NS | NS |
 CD16A -230A/Ta | 6 (9.8) | 12 (23.1) | 0.07 | NS | 7 (22.6) | NS | 5 (26.3) | NS | NS |
Allele | |||||||||
 CD16A -H48 (A)a | 6 (4.9) | 13 (12.5) | 0.05 | 2.761 | 7 (11.3) | NS | 6 (15.8) | 0.037 | 3.625 |
 CD16A -R48 (G) | 14 (11.5) | 6 (5.8) | NS |  | 3 (4.8) | NS | 3 (7.9) | NS |  |
 CD16A -L48 (T) | 102 (83.6) | 85 (81.7) | NS |  | 52 (83.9) | NS | 29 (76.3) | NS |  |